SCHEMBL3015010

SCHEMBL3015010

COc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cc(C(F)(F)F)ccc4Cl)CC3)n2)cc1

nearest known ligand 0.40

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 5/20 0.40
POLB P06746 2/20 0.40
LMNA P02545 2/20 0.40
GAA P10253 2/20 0.40
USP2 O75604 1/20 0.40
HTT P42858 1/20 0.40
MAPK10 P53779 1/20 0.40
ALDH1A1 P00352 3/20 0.38
CYP2C19 P33261 2/20 0.38
CYP3A4 P08684 1/20 0.38
CYP2D6 P10635 1/20 0.38
NPSR1 Q6W5P4 1/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 1/20 0.38
TSHR P16473 1/20 0.38
KMT2A Q03164 1/20 0.38
ATM Q13315 1/20 0.38
CTSS P25774 3/20 0.37
TP53 P04637 2/20 0.36
MAPT P10636 2/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3007437 0.92 CNR2 (0.38) SMN1; SMN2POLBLMNAGAAUSP2
SCHEMBL3016781 0.91 MAPT (0.39) SMN1; SMN2POLBLMNAGAAUSP2
SCHEMBL3021689 0.91 MEN1 (0.39) SMN1; SMN2POLBLMNAALDH1A1L3MBTL1
SCHEMBL3012889 0.91 ALDH1A1 (0.39) SMN1; SMN2LMNAALDH1A1NPSR1L3MBTL1
SCHEMBL3010474 0.91 MEN1 (0.41) SMN1; SMN2LMNAALDH1A1NPSR1L3MBTL1
SCHEMBL3002000 0.89 MEN1 (0.38) SMN1; SMN2POLBLMNAALDH1A1L3MBTL1
SCHEMBL3008296 0.89 ALDH1A1 (0.46) SMN1; SMN2POLBLMNAUSP2ALDH1A1
SCHEMBL2999661 0.89 MAPT (0.40) SMN1; SMN2POLBLMNAALDH1A1MEN1
SCHEMBL3003881 0.89 MEN1 (0.41) SMN1; SMN2POLBLMNAHTTALDH1A1
SCHEMBL3022829 0.87 MEN1 (0.39) SMN1; SMN2LMNAALDH1A1L3MBTL1MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA SMN1; SMN2 1/4885POLB 4649/4885LMNA 80/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.